<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250414230019&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250414230019&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 15 Apr 2025 03:00:21 +0000</lastbuilddate>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Assessing the Consequences of Retrograde and Transseptal Approaches to Ventricular Arrhythmia Ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228071/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):1060-1062. doi: 10.1161/CIRCULATIONAHA.125.073626. Epub 2025 Apr 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228071/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228071</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073626>10.1161/CIRCULATIONAHA.125.073626</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228071</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Nikolas Nozica</dc:creator>
<dc:creator>Usha Tedrow</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Assessing the Consequences of Retrograde and Transseptal Approaches to Ventricular Arrhythmia Ablation</dc:title>
<dc:identifier>pmid:40228071</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073626</dc:identifier>
</item>
<item>
<title>Correction to: Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228070/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):e956. doi: 10.1161/CIR.0000000000001333. Epub 2025 Apr 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228070/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228070</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001333>10.1161/CIR.0000000000001333</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228070</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Zongna Ren</dc:creator>
<dc:creator>Peng Yu</dc:creator>
<dc:creator>Dandan Li</dc:creator>
<dc:creator>Zheng Li</dc:creator>
<dc:creator>Yingnan Liao</dc:creator>
<dc:creator>Yin Wang</dc:creator>
<dc:creator>Bingying Zhou</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Single-Cell Reconstruction of Progression Trajectory Reveals Intervention Principles in Pathological Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:40228070</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001333</dc:identifier>
</item>
<item>
<title>Reprogrammed Smooth Muscle Cells for Vascular Repair: A New Path to Healing Ischemic Tissue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):1095-1097. doi: 10.1161/CIRCULATIONAHA.124.072958. Epub 2025 Apr 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228069</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072958>10.1161/CIRCULATIONAHA.124.072958</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228069</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Li Qian</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Reprogrammed Smooth Muscle Cells for Vascular Repair: A New Path to Healing Ischemic Tissue</dc:title>
<dc:identifier>pmid:40228069</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072958</dc:identifier>
</item>
<item>
<title>Response by Peigh et al to Letter Regarding Article, "Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228068/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):e925. doi: 10.1161/CIRCULATIONAHA.124.072692. Epub 2025 Apr 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228068/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228068</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072692>10.1161/CIRCULATIONAHA.124.072692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228068</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Graham Peigh</dc:creator>
<dc:creator>Sarah C Rosemas</dc:creator>
<dc:creator>Anthony I Roberts</dc:creator>
<dc:creator>Colleen Longacre</dc:creator>
<dc:creator>Rod S Passman</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Peigh et al to Letter Regarding Article, "Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices"</dc:title>
<dc:identifier>pmid:40228068</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072692</dc:identifier>
</item>
<item>
<title>G-Protein-Coupled Estrogen Receptor 1 and Pregnancy Confer Protection Against Hypertension in Older Females</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228067/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):1126-1129. doi: 10.1161/CIRCULATIONAHA.124.073693. Epub 2025 Apr 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228067/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228067</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073693>10.1161/CIRCULATIONAHA.124.073693</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228067</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Ravneet Singh</dc:creator>
<dc:creator>Supaporn Kulthinee</dc:creator>
<dc:creator>Victoria L Nasci</dc:creator>
<dc:creator>Elvis A Akwo</dc:creator>
<dc:creator>Chibundu Juliet Umunna</dc:creator>
<dc:creator>Rawan N Almutlaq</dc:creator>
<dc:creator>Oleh M Pochynyuk</dc:creator>
<dc:creator>Cassianne Robinson-Cohen</dc:creator>
<dc:creator>Eman Y Gohar</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>G-Protein-Coupled Estrogen Receptor 1 and Pregnancy Confer Protection Against Hypertension in Older Females</dc:title>
<dc:identifier>pmid:40228067</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073693</dc:identifier>
</item>
<item>
<title>Dose Response of Incidental Physical Activity Against Cardiovascular Events and Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228066/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Any daily IPA amount of vigorous or moderate intensity was associated with lower CVD risk in a dose-response manner. LIPA had weak associations with all outcomes. One minute of vigorous or ≈3.0 to 3.5 minutes of moderate IPA was associated with a similar degree of lower CVD risk. Our findings highlight the potential cardiovascular health value of incidental physical activity, especially for people who struggle to do structured exercise.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):1063-1075. doi: 10.1161/CIRCULATIONAHA.124.072253. Epub 2025 Apr 14.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Few middle-aged and older adults engage in regular leisure-time exercise. Incidental physical activity (IPA) encompasses activities of daily living outside the leisure-time domain. No dose-response study is available to guide IPA-focused interventions and guidelines. We examined the associations of device-assessed IPA intensities (vigorous [VIPA], moderate [MIPA], light [LIPA]) with major adverse cardiovascular events (MACE) and mortality, and we estimated the "health equivalence" of LIPA and MIPA against 1 minute of VIPA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 24 139 nonexercisers from the 2013 to 2015 UK Biobank accelerometry substudy (56.2% women) with a mean±SD age of 61.9±7.6 years were analyzed using a prospective cohort design. IPA energy expenditure and daily durations of VIPA, MIPA, and LIPA were calculated with a validated machine learning-based intensity classifier. MACE included incident stroke, myocardial infarction, and heart failure; CVD death; CVD mortality; and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Analyses included 22 107 (MACE), 22 174 (CVD mortality), and 24 139 (all-cause mortality) participants, corresponding to 908/223/1071 events over 7.9 years of follow-up. IPA volume exhibited an L-shaped association with a nadir at ≈35 to 38 kJ·kg<sup>-1</sup>·d<sup>-1</sup>, corresponding to hazard ratios of 0.49 (95% CI, 0.39-0.61) for MACE, 0.33 (95% CI, 0.22-0.52) for CVD mortality, and 0.31 (95% CI, 0.25-0.38) for all-cause mortality. Any amounts of VIPA or MIPA were associated with lower risk, with a plateau of ≈14 minutes per day (VIPA) and 34 to 50 minutes per day (MIPA). The median VIPA (4.6 min/d) and MIPA (23.8 min/d) durations were associated with CVD mortality hazard ratio of 0.62 (95% CI, 0.46-0.83) and 0.50 (95% CI, 0.31-0.80), respectively. LIPA showed a subtle inverse gradient which was statistically significant only for CVD mortality at levels >;130 minutes per day. One minute of VIPA was equivalent to 2.8 (MACE) to 3.4 (CVD mortality) minutes of MIPA and 34.7 (CVD mortality) to 48.5 (MACE) minutes of LIPA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Any daily IPA amount of vigorous or moderate intensity was associated with lower CVD risk in a dose-response manner. LIPA had weak associations with all outcomes. One minute of vigorous or ≈3.0 to 3.5 minutes of moderate IPA was associated with a similar degree of lower CVD risk. Our findings highlight the potential cardiovascular health value of incidental physical activity, especially for people who struggle to do structured exercise.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228066</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072253>10.1161/CIRCULATIONAHA.124.072253</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228066</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Emmanuel Stamatakis</dc:creator>
<dc:creator>Raaj K Biswas</dc:creator>
<dc:creator>Nicholas A Koemel</dc:creator>
<dc:creator>Angelo Sabag</dc:creator>
<dc:creator>Richard Pulsford</dc:creator>
<dc:creator>Andrew J Atkin</dc:creator>
<dc:creator>Afroditi Stathi</dc:creator>
<dc:creator>Sonia Cheng</dc:creator>
<dc:creator>Cecilie Thøgersen-Ntoumani</dc:creator>
<dc:creator>Joanna M Blodgett</dc:creator>
<dc:creator>Adrian Bauman</dc:creator>
<dc:creator>Carlos Celis-Morales</dc:creator>
<dc:creator>Mark Hamer</dc:creator>
<dc:creator>Jason M R Gill</dc:creator>
<dc:creator>Matthew N Ahmadi</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dose Response of Incidental Physical Activity Against Cardiovascular Events and Mortality</dc:title>
<dc:identifier>pmid:40228066</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072253</dc:identifier>
</item>
<item>
<title>Patient-Reported Outcomes as End Points in Heart Failure Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228065/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>Heart failure is a growing health-care concern affecting tens of millions of individuals globally. Although traditional therapeutic strategies have focused on reducing the risk for hospitalization and mortality, the importance of patient-reported outcomes (PROs) in patients with heart failure is increasingly being recognized. Regulatory agencies consider PROs part of their evaluation of drugs and devices, and professional society guidelines may recommend interventions that improve PROs. However,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):1111-1125. doi: 10.1161/CIRCULATIONAHA.124.072158. Epub 2025 Apr 14.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure is a growing health-care concern affecting tens of millions of individuals globally. Although traditional therapeutic strategies have focused on reducing the risk for hospitalization and mortality, the importance of patient-reported outcomes (PROs) in patients with heart failure is increasingly being recognized. Regulatory agencies consider PROs part of their evaluation of drugs and devices, and professional society guidelines may recommend interventions that improve PROs. However, for several reasons, the effect of interventions on PROs reported in heart failure trials currently is difficult to interpret. There is no consensus on the timing and frequency of PRO assessments. Moreover, it has been difficult to establish a minimal clinically important difference, that is, the minimal change in a PRO score that is meaningful to a patient. In addition, traditional methods of analyzing and reporting PROs such as comparison of mean differences across groups or responder analysis are prone to statistical artifacts and misinterpretation. This article presents an in-depth discussion of these issues, with the Kansas City Cardiomyopathy Questionnaire used as an example, to facilitate the use of PROs in heart failure research, regulatory, and clinical settings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228065/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228065</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072158>10.1161/CIRCULATIONAHA.124.072158</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228065</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Muhammad Shariq Usman</dc:creator>
<dc:creator>Charu Gandotra</dc:creator>
<dc:creator>Ali Salman</dc:creator>
<dc:creator>Andrew Farb</dc:creator>
<dc:creator>Aliza M Thompson</dc:creator>
<dc:creator>Norman Stockbridge</dc:creator>
<dc:creator>Cordula Zeller</dc:creator>
<dc:creator>Folke Folkvaljon</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Patient-Reported Outcomes as End Points in Heart Failure Trials</dc:title>
<dc:identifier>pmid:40228065</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072158</dc:identifier>
</item>
<item>
<title>Letter by Lu et al Regarding Article, "Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40228064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 15;151(15):e923-e924. doi: 10.1161/CIRCULATIONAHA.124.071418. Epub 2025 Apr 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40228064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40228064</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071418>10.1161/CIRCULATIONAHA.124.071418</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40228064</guid>
<pubDate>Mon, 14 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiaofeng Lu</dc:creator>
<dc:creator>Shaowen Liu</dc:creator>
<dc:creator>Songwen Chen</dc:creator>
<dc:date>2025-04-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Lu et al Regarding Article, "Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices"</dc:title>
<dc:identifier>pmid:40228064</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071418</dc:identifier>
</item>
<item>
<title>An Arabidopsis single-nucleus atlas decodes leaf senescence and nutrient allocation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40220755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>With rapid advancements in single-cell RNA sequencing (scRNA-seq) technologies, exploration of the systemic coordination of critical physiological processes has entered a new era. Here, we generated a comprehensive Arabidopsis single-nucleus transcriptomic atlas using over 1 million nuclei from 20 tissues encompassing multiple developmental stages. Our analyses identified cell types that have not been characterized in previous single-protoplast studies and revealed cell-type conservation and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 10:S0092-8674(25)00297-1. doi: 10.1016/j.cell.2025.03.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">With rapid advancements in single-cell RNA sequencing (scRNA-seq) technologies, exploration of the systemic coordination of critical physiological processes has entered a new era. Here, we generated a comprehensive Arabidopsis single-nucleus transcriptomic atlas using over 1 million nuclei from 20 tissues encompassing multiple developmental stages. Our analyses identified cell types that have not been characterized in previous single-protoplast studies and revealed cell-type conservation and specificity across different organs. Through time-resolved sampling, we revealed highly coordinated onset and progression of senescence among the major leaf cell types. We originally formulated two molecular indexes to quantify the aging state of leaf cells at single-cell resolution. Additionally, facilitated by weighted gene co-expression network analysis, we identified hundreds of promising hub genes that may integratively regulate leaf senescence. Inspired by the functional validation of identified hub genes, we built a systemic scenario of carbon and nitrogen allocation among different cell types from source leaves to sink organs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40220755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40220755</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.024>10.1016/j.cell.2025.03.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40220755</guid>
<pubDate>Sat, 12 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Xing Guo</dc:creator>
<dc:creator>Yichuan Wang</dc:creator>
<dc:creator>Caiyao Zhao</dc:creator>
<dc:creator>Cong Tan</dc:creator>
<dc:creator>Wei Yan</dc:creator>
<dc:creator>Sunhuan Xiang</dc:creator>
<dc:creator>Dan Zhang</dc:creator>
<dc:creator>Hui Zhang</dc:creator>
<dc:creator>Mengting Zhang</dc:creator>
<dc:creator>Liujing Yang</dc:creator>
<dc:creator>Meng Yan</dc:creator>
<dc:creator>Pingli Xie</dc:creator>
<dc:creator>Yi Wang</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Dongming Fang</dc:creator>
<dc:creator>Xuanmin Guang</dc:creator>
<dc:creator>Wenwen Shao</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:creator>Haoxuan Wang</dc:creator>
<dc:creator>Sunil Kumar Sahu</dc:creator>
<dc:creator>Min Liu</dc:creator>
<dc:creator>Tong Wei</dc:creator>
<dc:creator>Yang Peng</dc:creator>
<dc:creator>Yuping Qiu</dc:creator>
<dc:creator>Tao Peng</dc:creator>
<dc:creator>Yi Zhang</dc:creator>
<dc:creator>Xuemei Ni</dc:creator>
<dc:creator>Zhicheng Xu</dc:creator>
<dc:creator>Haorong Lu</dc:creator>
<dc:creator>Zhonghai Li</dc:creator>
<dc:creator>Huanming Yang</dc:creator>
<dc:creator>Ertao Wang</dc:creator>
<dc:creator>Michael Lisby</dc:creator>
<dc:creator>Huan Liu</dc:creator>
<dc:creator>Hongwei Guo</dc:creator>
<dc:creator>Xun Xu</dc:creator>
<dc:date>2025-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>An Arabidopsis single-nucleus atlas decodes leaf senescence and nutrient allocation</dc:title>
<dc:identifier>pmid:40220755</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.024</dc:identifier>
</item>
<item>
<title>Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40220754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>Chimeric antigen receptor (CAR) T cell immunotherapy represents a breakthrough in the treatment of hematological malignancies, but poor specificity has limited its applicability to solid tumors. By contrast, natural T cells harboring T cell receptors (TCRs) can discriminate between neoantigen-expressing cancer cells and self-antigen-expressing healthy tissues but have limited potency against tumors. We used a high-throughput platform to systematically evaluate the impact of co-expressing a TCR...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 10:S0092-8674(25)00290-9. doi: 10.1016/j.cell.2025.03.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chimeric antigen receptor (CAR) T cell immunotherapy represents a breakthrough in the treatment of hematological malignancies, but poor specificity has limited its applicability to solid tumors. By contrast, natural T cells harboring T cell receptors (TCRs) can discriminate between neoantigen-expressing cancer cells and self-antigen-expressing healthy tissues but have limited potency against tumors. We used a high-throughput platform to systematically evaluate the impact of co-expressing a TCR and CAR on the same CAR T cell. While strong TCR-antigen interactions enhanced CAR activation, weak TCR-antigen interactions actively antagonized their activation. Mathematical modeling captured this TCR-CAR crosstalk in CAR T cells, allowing us to engineer dual TCR/CAR T cells targeting neoantigens (HHAT<sup>L8F</sup>/p53<sup>R175H</sup>) and human epithelial growth factor receptor 2 (HER2) ligands, respectively. These T cells exhibited superior anti-cancer activity and minimal toxicity against healthy tissue compared with conventional CAR T cells in a humanized solid tumor mouse model. Harnessing pre-existing inhibitory crosstalk between receptors, therefore, paves the way for the design of more precise cancer immunotherapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40220754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40220754</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.017>10.1016/j.cell.2025.03.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40220754</guid>
<pubDate>Sat, 12 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Taisuke Kondo</dc:creator>
<dc:creator>François X P Bourassa</dc:creator>
<dc:creator>Sooraj Achar</dc:creator>
<dc:creator>Justyn DuSold</dc:creator>
<dc:creator>Pablo F Céspedes</dc:creator>
<dc:creator>Makoto Ando</dc:creator>
<dc:creator>Alka Dwivedi</dc:creator>
<dc:creator>Josquin Moraly</dc:creator>
<dc:creator>Christopher Chien</dc:creator>
<dc:creator>Saliha Majdoul</dc:creator>
<dc:creator>Adam L Kenet</dc:creator>
<dc:creator>Madison Wahlsten</dc:creator>
<dc:creator>Audun Kvalvaag</dc:creator>
<dc:creator>Edward Jenkins</dc:creator>
<dc:creator>Sanghyun P Kim</dc:creator>
<dc:creator>Catherine M Ade</dc:creator>
<dc:creator>Zhiya Yu</dc:creator>
<dc:creator>Guillaume Gaud</dc:creator>
<dc:creator>Marco Davila</dc:creator>
<dc:creator>Paul Love</dc:creator>
<dc:creator>James C Yang</dc:creator>
<dc:creator>Michael L Dustin</dc:creator>
<dc:creator>Grégoire Altan-Bonnet</dc:creator>
<dc:creator>Paul François</dc:creator>
<dc:creator>Naomi Taylor</dc:creator>
<dc:date>2025-04-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity</dc:title>
<dc:identifier>pmid:40220754</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.017</dc:identifier>
</item>
<item>
<title>Extracellular respiration is a latent energy metabolism in Escherichia coli</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40215961/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>Diverse microbes utilize redox shuttles to exchange electrons with their environment through mediated extracellular electron transfer (EET), supporting anaerobic survival. Although mediated EET has been leveraged for bioelectrocatalysis for decades, fundamental questions remain about how these redox shuttles are reduced within cells and their role in cellular bioenergetics. Here, we integrate genome editing, electrochemistry, and systems biology to investigate the mechanism and bioenergetics of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Apr 4:S0092-8674(25)00289-2. doi: 10.1016/j.cell.2025.03.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Diverse microbes utilize redox shuttles to exchange electrons with their environment through mediated extracellular electron transfer (EET), supporting anaerobic survival. Although mediated EET has been leveraged for bioelectrocatalysis for decades, fundamental questions remain about how these redox shuttles are reduced within cells and their role in cellular bioenergetics. Here, we integrate genome editing, electrochemistry, and systems biology to investigate the mechanism and bioenergetics of mediated EET in Escherichia coli, elusive for over two decades. In the absence of alternative electron sinks, the redox cycling of 2-hydroxy-1,4-naphthoquinone (HNQ) via the cytoplasmic nitroreductases NfsB and NfsA enables E. coli respiration on an extracellular electrode. E. coli also exhibits rapid genetic adaptation in the outer membrane porin OmpC, enhancing HNQ-mediated EET levels coupled to growth. This work demonstrates that E. coli can grow independently of classic electron transport chains and fermentation, unveiling a potentially widespread new type of anaerobic energy metabolism.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40215961/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40215961</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.03.016>10.1016/j.cell.2025.03.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40215961</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Biki Bapi Kundu</dc:creator>
<dc:creator>Jayanth Krishnan</dc:creator>
<dc:creator>Richard Szubin</dc:creator>
<dc:creator>Arjun Patel</dc:creator>
<dc:creator>Bernhard O Palsson</dc:creator>
<dc:creator>Daniel C Zielinski</dc:creator>
<dc:creator>Caroline M Ajo-Franklin</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Extracellular respiration is a latent energy metabolism in Escherichia coli</dc:title>
<dc:identifier>pmid:40215961</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.03.016</dc:identifier>
</item>
<item>
<title>Correction to: Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40215189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 11:ehaf217. doi: 10.1093/eurheartj/ehaf217. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40215189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40215189</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf217>10.1093/eurheartj/ehaf217</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40215189</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:date>2025-04-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study)</dc:title>
<dc:identifier>pmid:40215189</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf217</dc:identifier>
</item>
<item>
<title>Rosai-Dorfman disease of the ascending aorta and pulmonary artery mimicking intramural hematoma and mass</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40214969/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 11:ehaf250. doi: 10.1093/eurheartj/ehaf250. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40214969/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40214969</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf250>10.1093/eurheartj/ehaf250</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40214969</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Lijuan Qian</dc:creator>
<dc:creator>Jie Yu</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rosai-Dorfman disease of the ascending aorta and pulmonary artery mimicking intramural hematoma and mass</dc:title>
<dc:identifier>pmid:40214969</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf250</dc:identifier>
</item>
<item>
<title>Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40214750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>Treatment-resistant hypertension (TRH) often coexists with chronic kidney disease (CKD), and the presence of both conditions increases the risk of adverse cardiovascular outcomes. Patients with TRH and CKD exhibit enhanced aldosterone and mineralocorticoid receptor expression, which promote inflammation and fibrosis in cardiac and renal tissues, contributing to the development and progression of cardiorenal diseases. Both achieving optimal blood pressure (BP) control and mitigating the risk of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 11:ehaf225. doi: 10.1093/eurheartj/ehaf225. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Treatment-resistant hypertension (TRH) often coexists with chronic kidney disease (CKD), and the presence of both conditions increases the risk of adverse cardiovascular outcomes. Patients with TRH and CKD exhibit enhanced aldosterone and mineralocorticoid receptor expression, which promote inflammation and fibrosis in cardiac and renal tissues, contributing to the development and progression of cardiorenal diseases. Both achieving optimal blood pressure (BP) control and mitigating the risk of aldosterone-related adverse events are cornerstones in the management of patients with TRH and CKD. Mineralocorticoid receptor antagonists (MRAs) are recommended for the treatment of TRH. To date, the efficacy has been investigated in populations with mostly normal renal function. However, the potential risk of hyperkalaemia limits the use of MRAs, particularly in patients with CKD. Non-steroidal MRAs and sodium glucose cotransporter-2 inhibitors have slowed renal function decline and shown cardiorenal benefits. Additionally, aldosterone synthase inhibitors may emerge as a therapeutic option for patients with TRH. Clinical trials for TRH primarily centred on assessing BP-lowering effects; however, merely lowering BP might not be a sufficient target to prevent a risk of cardiorenal disease progression. This paper presents evidence and potential benefits of aldosterone-targeted therapy in the treatment of TRH and CKD and re-consider the treatment strategies in clinical practice and trial design.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40214750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40214750</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf225>10.1093/eurheartj/ehaf225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40214750</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Masatake Kobayashi</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Patrick Rossignol</dc:creator>
<dc:creator>Nicolas Girerd</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease</dc:title>
<dc:identifier>pmid:40214750</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf225</dc:identifier>
</item>
<item>
<title>Infective endocarditis: it takes a team</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40214743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>Infective endocarditis (IE) is a relatively rare but life-threatening systemic infection, which remains associated with high morbidity and mortality. The epidemiology of IE has shifted to involve an increasing numbers of older patients with both cardiovascular and other types of prosthetic devices, multiple comorbid conditions often requiring invasive procedures, increasingly virulent pathogens, in particular Staphylococcus aureus, or that can harbour anti-microbial resistance, and an escalation...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 11:ehaf219. doi: 10.1093/eurheartj/ehaf219. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Infective endocarditis (IE) is a relatively rare but life-threatening systemic infection, which remains associated with high morbidity and mortality. The epidemiology of IE has shifted to involve an increasing numbers of older patients with both cardiovascular and other types of prosthetic devices, multiple comorbid conditions often requiring invasive procedures, increasingly virulent pathogens, in particular Staphylococcus aureus, or that can harbour anti-microbial resistance, and an escalation of injection drug use in many areas of the world. In parallel, advancements in diagnostic and therapeutic options have led to complex strategies in patients' management. Despite these epidemiologic shifts, clinical trials have been rare and most of the evidence guiding IE management derives from expert consensus or analysis of large registries. Because of this, a multi-disciplinary IE team-based approach has been recommended as the standard of care. The aim of this review is to explore the rationale for a multi-disciplinary team-based approach to the management of IE. This approach has proved to be potentially beneficial based on multiple investigations that have evaluated patient outcomes. In addition, implementation strategies, feasibility and options of the team approach have also been highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40214743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40214743</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf219>10.1093/eurheartj/ehaf219</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40214743</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Lawrence Lau</dc:creator>
<dc:creator>Larry Baddour</dc:creator>
<dc:creator>Núria Fernández Hidalgo</dc:creator>
<dc:creator>Thomas D Brothers</dc:creator>
<dc:creator>William K F Kong</dc:creator>
<dc:creator>Michael A Borger</dc:creator>
<dc:creator>Xavier Duval</dc:creator>
<dc:creator>Christophe Tribouilloy</dc:creator>
<dc:creator>Jean-Francois Obadia</dc:creator>
<dc:creator>Mehrdad Golian</dc:creator>
<dc:creator>Vicente F Corrales-Medina</dc:creator>
<dc:creator>Francois Auclair</dc:creator>
<dc:creator>Mikael Mazighi</dc:creator>
<dc:creator>Kwan Leung Chan</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Gilbert Habib</dc:creator>
<dc:creator>Fraser D Rubens</dc:creator>
<dc:creator>David Messika-Zeitoun</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Infective endocarditis: it takes a team</dc:title>
<dc:identifier>pmid:40214743</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf219</dc:identifier>
</item>
<item>
<title>Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40214301/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Apr 11:ehaf214. doi: 10.1093/eurheartj/ehaf214. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40214301/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40214301</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf214>10.1093/eurheartj/ehaf214</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40214301</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Jan Borén</dc:creator>
<dc:creator>Chris Packard</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:creator>Alberico L Catapano</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease</dc:title>
<dc:identifier>pmid:40214301</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf214</dc:identifier>
</item>
<item>
<title>Heart Has Intrinsic Ketogenic Capacity that Mediates NAD&lt;sup>;+&lt;/sup>; Therapy in HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40211954/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The canonical ketogenic enzyme, HMGCS2, mediates the therapeutic effects of the oxidized form of nicotinamide adenine dinucleotide repletion in HFpEF by restoring normal lipid metabolism and mitochondrial function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11. doi: 10.1161/CIRCRESAHA.124.325550. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has overtaken heart failure with reduced ejection fraction as the leading type of heart failure globally and is marked by high morbidity and mortality rates, yet with only a single approved pharmacotherapy: SGLT2i (sodium-glucose co-transporter 2 inhibitor). A prevailing theory for the mechanism underlying SGLT2i is nutrient deprivation signaling, of which ketogenesis is a hallmark. However, it is unclear whether the canonical ketogenic enzyme, HMGCS2 (3-hydroxy-3-methylglutaryl-coenzyme A synthase 2), plays any cardiac role in HFpEF pathogenesis or therapeutic response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used human myocardium, human HFpEF and heart failure with reduced ejection fraction transcardiac blood sampling, an established murine model of HFpEF, ex vivo Langendorff perfusion, stable isotope tracing in isolated cardiomyocytes, targeted metabolomics, proteomics, lipidomics, and a novel cardiomyocyte-specific conditional HMGCS2-deficient model that we generated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrate, for the first time, the intrinsic capacity of the human heart to produce ketones via HMGCS2. We found that increased acetylation of HMGCS2 led to a decrease in the enzyme's specific activity. However, this was overcome by an increase in the steady-state levels of protein. Oxidized form of nicotinamide adenine dinucleotide repletion restored HMGCS2 function via deacetylation, increased fatty acid oxidation, and rescued cardiac function in HFpEF. Critically, using a conditional, cardiomyocyte-specific HMGCS2 knockdown murine model, we revealed that the oxidized form of nicotinamide adenine dinucleotide is unable to rescue HFpEF in the absence of cardiomyocyte HMGCS2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The canonical ketogenic enzyme, HMGCS2, mediates the therapeutic effects of the oxidized form of nicotinamide adenine dinucleotide repletion in HFpEF by restoring normal lipid metabolism and mitochondrial function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40211954/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40211954</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325550>10.1161/CIRCRESAHA.124.325550</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40211954</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yen Chin Koay</dc:creator>
<dc:creator>Bailey McIntosh</dc:creator>
<dc:creator>Yann Huey Ng</dc:creator>
<dc:creator>Yang Cao</dc:creator>
<dc:creator>XiaoSuo Wang</dc:creator>
<dc:creator>Yanchuang Han</dc:creator>
<dc:creator>Saki Tomita</dc:creator>
<dc:creator>Angela Yu Bai</dc:creator>
<dc:creator>Benjamin Hunter</dc:creator>
<dc:creator>Ashish Misra</dc:creator>
<dc:creator>Christopher M Loughrey</dc:creator>
<dc:creator>Paul G Bannon</dc:creator>
<dc:creator>Sean Lal</dc:creator>
<dc:creator>Aldons J Lusis</dc:creator>
<dc:creator>David M Kaye</dc:creator>
<dc:creator>Mark Larance</dc:creator>
<dc:creator>John F O'Sullivan</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Heart Has Intrinsic Ketogenic Capacity that Mediates NAD&lt;sup>;+&lt;/sup>; Therapy in HFpEF</dc:title>
<dc:identifier>pmid:40211954</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325550</dc:identifier>
</item>
<item>
<title>Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40211947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Targeting SETD2 might prevent lipotoxic injury in cHFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Apr 11. doi: 10.1161/CIRCRESAHA.124.325310. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiometabolic heart failure with preserved ejection fraction (cHFpEF) is a highly prevalent and deadly condition. Histone 3 trimethylation at lysine 36 (H3k36me3)-a chromatin signature induced by the histone methyltransferase SETD2 (SET domain containing 2)-correlates with changes in gene expression in human failing hearts; however, its role remains poorly understood. This study investigates the role of SETD2 in cHFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Chromatin immunoprecipitation sequencing and RNA sequencing were used to investigate H3k36me3-related transcriptional regulation. Mice with cardiomyocyte-specific deletion of SETD2 (c-SETD2<sup>-/-</sup>) were generated and subjected to high-fat diet feeding and L-NAME treatment for 15 weeks to induce cHFpEF. Cardiac function and exercise tolerance were assessed by echocardiography and treadmill exhaustion test. A selective pharmacological inhibitor of SETD2, EZM0414, was also tested in cHFpEF mice. Mechanistic experiments were performed in cultured cardiomyocytes exposed to palmitic acid. SETD2 signaling and the effects of EZM0414 were also investigated in cardiomyocytes from patients with cHFpEF and control donors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SETD2 was upregulated in cHFpEF mouse hearts, and its chromatin mark H3k36me3 was involved in lipid metabolism and highly enriched on the promoter of the <i>Srebf1</i> gene, encoding for SREBP1 (sterol regulatory binding protein 1). SETD2 activation in cHFpEF led to SREBP1 upregulation, triglyceride accumulation, and lipotoxic damage. Of note, cardiomyocyte-specific deletion of SETD2 in mice prevented heart failure with preserved ejection fraction-related hypertrophy, diastolic dysfunction, and lung congestion while improving exercise tolerance. SETD2 deletion blunted H3K36me3 enrichment on <i>Srebf1</i> promoter, thus leading to a marked rewiring of the cardiac lipidome and restoration of autophagic flux. In vivo treatment with the SETD2 inhibitor EZM0414 recapitulated the effects of SETD2 deletion. Silencing of SETD2 in palmitic acid-treated cardiomyocytes prevented SREBP1 upregulation, whereas SETD2 overexpression mirrored lipotoxic damage. Finally, SETD2 was upregulated in left ventricle specimens from patients with cHFpEF while EZM0414 attenuated cardiomyocyte stiffness.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Targeting SETD2 might prevent lipotoxic injury in cHFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40211947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40211947</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325310>10.1161/CIRCRESAHA.124.325310</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40211947</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Sarah Costantino</dc:creator>
<dc:creator>Shafeeq A Mohammed</dc:creator>
<dc:creator>Samuele Ambrosini</dc:creator>
<dc:creator>Marialucia Telesca</dc:creator>
<dc:creator>Alessandro Mengozzi</dc:creator>
<dc:creator>Kaivalya Walavalkar</dc:creator>
<dc:creator>Era Gorica</dc:creator>
<dc:creator>Melissa Herwig</dc:creator>
<dc:creator>Loek van Heerebeek</dc:creator>
<dc:creator>Junyan Xia</dc:creator>
<dc:creator>Gergely Karsai</dc:creator>
<dc:creator>Thorsten Hornemann</dc:creator>
<dc:creator>Omer Dzemali</dc:creator>
<dc:creator>Raffaella Santoro</dc:creator>
<dc:creator>Qian Li</dc:creator>
<dc:creator>Frank Ruschitzka</dc:creator>
<dc:creator>Nazha Hamdani</dc:creator>
<dc:creator>Francesco Paneni</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Chromatin Rewiring by SETD2 Drives Lipotoxic Injury in Cardiometabolic HFpEF</dc:title>
<dc:identifier>pmid:40211947</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325310</dc:identifier>
</item>
<item>
<title>Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40211944/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Apr 11. doi: 10.1161/CIRCULATIONAHA.124.072340. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Whole-exome sequencing identified a novel <i>DSC2</i> sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with <i>Dsc2</i> sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. <i>Dsc2</i> mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in <i>Dsc2</i> knock-out mice. In addition, effects of <i>Dsc2</i> mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>Dsc2</i>-deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified <i>Myl7</i> as the most downregulated gene in the right ventricles of <i>Dsc2</i>-deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. <i>Dsc2</i> mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in <i>Dsc2</i>-deficient mice. Reduced <i>DSC2</i> and <i>MLC2a</i> expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by <i>DSC2</i> loss of function, supported by human and mouse data. Loss of <i>Myl7</i> contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. <i>Dsc2</i> mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40211944/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40211944</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072340>10.1161/CIRCULATIONAHA.124.072340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40211944</guid>
<pubDate>Fri, 11 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Yan Zou</dc:creator>
<dc:creator>Jing Lu</dc:creator>
<dc:creator>Zhipeng Lian</dc:creator>
<dc:creator>Jianguo Jia</dc:creator>
<dc:creator>Juan Shen</dc:creator>
<dc:creator>Qianhe Li</dc:creator>
<dc:creator>Jennifer Ming Jen Wong</dc:creator>
<dc:creator>Kejia Jin</dc:creator>
<dc:creator>Wendi Yan</dc:creator>
<dc:creator>Xinyue Ren</dc:creator>
<dc:creator>Yang Zhang</dc:creator>
<dc:creator>Chenxing Huang</dc:creator>
<dc:creator>Huanjie Yang</dc:creator>
<dc:creator>Feng Huang</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Junyu Zhai</dc:creator>
<dc:creator>Yamei Xu</dc:creator>
<dc:creator>Xialian Xu</dc:creator>
<dc:creator>Hang Yu</dc:creator>
<dc:creator>Yi Jin</dc:creator>
<dc:creator>Hui Gong</dc:creator>
<dc:creator>Jinzhong Lin</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:creator>Yuxiang Dai</dc:creator>
<dc:date>2025-04-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy</dc:title>
<dc:identifier>pmid:40211944</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072340</dc:identifier>
</item>
<item>
<title>Development of a miniature, bioresorbable, light-activated pacemaker</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40210756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 10. doi: 10.1038/s41569-025-01157-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40210756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40210756</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01157-8>10.1038/s41569-025-01157-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40210756</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Development of a miniature, bioresorbable, light-activated pacemaker</dc:title>
<dc:identifier>pmid:40210756</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01157-8</dc:identifier>
</item>
<item>
<title>No effect of cerebral embolic protection devices on stroke risk after TAVI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40210755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250414230019&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Apr 10. doi: 10.1038/s41569-025-01156-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40210755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250414230019&v=2.18.0.post9+e462414">40210755</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01156-9>10.1038/s41569-025-01156-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40210755</guid>
<pubDate>Thu, 10 Apr 2025 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2025-04-10</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>No effect of cerebral embolic protection devices on stroke risk after TAVI</dc:title>
<dc:identifier>pmid:40210755</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01156-9</dc:identifier>
</item>





























</channel>
</rss>